Jefferies Initiates Coverage On Caris Life Sciences with Buy Rating, Announces Price Target of $28

Benzinga Newsdesk www.benzinga.com Neutral 70.0%

Neg 0% Neu 70% Pos 0%

Jefferies analyst Tycho Peterson initiates coverage on Caris Life Sciences (NASDAQ:CAI) with a Buy rating and announces Price Target of $28.